AML/MDS research hub

Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients

This study looks at adding a new drug, midostaurin, to a standard treatment called decitabine for adults with certain types of blood cancers (AML or high-risk MDS). The goal is to see if this combination is safe and works better for patients who can't have intense chemotherapy.